tradingkey.logo
tradingkey.logo
Search

Taysha Gene Therapies Inc

TSHA
Add to Watchlist
5.860USD
-0.015-0.26%
Close 07-31 16:00ETQuotes delayed by 15 min
1.87BMarket Cap
LossP/E TTM

TSHA Income Statement

You can find the annual or quarterly income statement of Taysha Gene Therapies Inc here for insights into the performance and operational efficiency of Taysha Gene Therapies Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
Total revenue
-100.00%0.00
171.27%5.49M
-100.00%0.00
78.60%1.99M
-32.51%2.30M
-43.90%2.02M
-62.33%1.79M
-53.57%1.11M
-27.52%3.41M
44.04%3.60M
--4.75M
--2.40M
--4.71M
--2.50M
--0.00
--0.00
--0.00
----
----
----
----
----
----
Revenue
-100.00%0.00
171.27%5.49M
-100.00%0.00
78.60%1.99M
-32.51%2.30M
-43.90%2.02M
-62.33%1.79M
-53.57%1.11M
-27.52%3.41M
44.04%3.60M
--4.75M
--2.40M
--4.71M
--2.50M
--0.00
--0.00
--0.00
----
----
----
----
----
----
Operating expenses
83.31%43.49M
53.89%33.78M
48.91%34.02M
28.24%28.74M
-14.48%23.72M
13.16%21.95M
12.11%22.85M
-13.06%22.41M
30.45%27.74M
-8.49%19.40M
-19.94%20.38M
-22.75%25.78M
-57.17%21.27M
-57.36%21.20M
-49.77%25.46M
-18.15%33.37M
54.72%49.65M
170.72%49.72M
236.95%50.68M
--40.77M
--32.09M
--18.37M
--15.04M
R&D expenses
117.21%33.81M
62.82%24.95M
72.25%25.75M
33.62%20.14M
-24.65%15.56M
20.84%15.32M
26.76%14.95M
-23.84%15.07M
65.07%20.66M
-8.51%12.68M
-29.71%11.79M
-15.80%19.79M
-67.23%12.51M
-63.44%13.86M
-57.56%16.77M
-23.29%23.51M
60.07%38.18M
209.28%37.92M
257.49%39.53M
--30.64M
--23.85M
--12.26M
--11.06M
Depreciation, depletion, and amortization
-1.67%295.00K
-1.32%300.00K
-4.67%286.00K
-6.83%300.00K
-7.69%300.00K
-24.00%304.00K
-9.37%300.00K
-19.50%322.00K
-1.81%325.00K
0.00%400.00K
10.33%331.00K
33.33%400.00K
10.33%331.00K
91.39%400.00K
80.72%300.00K
252.94%300.00K
837.50%300.00K
3383.33%209.00K
--166.00K
--85.00K
--32.00K
--6.00K
----
Operating profit
-103.01%-43.49M
-41.98%-28.30M
-61.56%-34.02M
-25.61%-26.75M
11.96%-21.42M
-26.18%-19.93M
-34.71%-21.06M
8.92%-21.30M
-46.93%-24.33M
15.52%-15.80M
38.59%-15.63M
29.93%-23.38M
66.65%-16.56M
62.39%-18.70M
49.77%-25.46M
18.15%-33.37M
-54.72%-49.65M
-170.72%-49.72M
-236.95%-50.68M
---40.77M
---32.09M
---18.37M
---15.04M
Net non-operating interest income (expenses)
Non-operating interest income
95.02%2.59M
68.82%2.87M
50.40%3.17M
29.10%1.86M
-21.68%1.33M
-11.50%1.70M
89.99%2.11M
545.74%1.44M
430.72%1.69M
865.33%1.92M
12222.22%1.11M
725.93%223.00K
2178.57%319.00K
586.21%199.00K
-75.68%9.00K
-32.50%27.00K
-78.79%14.00K
-40.82%29.00K
--37.00K
--40.00K
--66.00K
--49.00K
----
Non-operating interest expense
-52.63%9.00K
-45.45%12.00K
-37.50%15.00K
-37.04%17.00K
-34.48%19.00K
-96.91%22.00K
-98.37%24.00K
-98.13%27.00K
-97.89%29.00K
-10.43%713.00K
36.46%1.47M
93.81%1.44M
104.46%1.37M
15.20%796.00K
98.53%1.08M
282.99%743.00K
--672.00K
--691.00K
54200.00%543.00K
--194.00K
--0.00
--0.00
--1.00K
Special income (expenses)
-2.94%-1.47M
-411.61%-2.38M
71.76%-1.83M
-59.96%-1.73M
-2.73%-1.43M
-100.75%-465.00K
93.60%-6.47M
---1.08M
---1.39M
271.21%62.35M
---101.07M
----
----
---36.42M
--0.00
----
----
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Other non-operating income (expenses)
-338.46%-31.00K
54.55%-30.00K
54.32%-37.00K
-664.29%-237.00K
360.00%13.00K
-186.96%-66.00K
-326.32%-81.00K
1300.00%42.00K
37.50%-5.00K
-283.33%-23.00K
-1800.00%-19.00K
200.00%3.00K
0.00%-8.00K
---6.00K
---1.00K
---3.00K
---8.00K
----
----
----
----
----
----
Income before tax
-96.99%-42.41M
-48.26%-27.85M
-28.24%-32.73M
-28.45%-26.88M
10.52%-21.53M
-139.35%-18.79M
78.20%-25.52M
14.92%-20.93M
-36.54%-24.06M
185.68%47.74M
-341.39%-117.09M
27.85%-24.60M
64.98%-17.62M
-10.59%-55.72M
48.18%-26.53M
16.70%-34.09M
-57.12%-50.32M
-175.06%-50.39M
-240.29%-51.19M
---40.93M
---32.02M
---18.32M
---15.04M
Income tax
--0.00
--0.00
----
----
--0.00
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income after tax
-96.99%-42.41M
-48.26%-27.85M
-28.24%-32.73M
-28.45%-26.88M
10.52%-21.53M
-139.35%-18.79M
78.20%-25.52M
14.92%-20.93M
-36.54%-24.06M
185.68%47.74M
-341.39%-117.09M
27.85%-24.60M
64.98%-17.62M
-10.59%-55.72M
48.18%-26.53M
16.70%-34.09M
-57.12%-50.32M
-175.06%-50.39M
-240.29%-51.19M
---40.93M
---32.02M
---18.32M
---15.04M
Net income from continuous operations
-96.99%-42.41M
-48.26%-27.85M
-28.24%-32.73M
-28.45%-26.88M
10.52%-21.53M
-139.35%-18.79M
78.20%-25.52M
14.92%-20.93M
-36.54%-24.06M
185.68%47.74M
-341.39%-117.09M
27.85%-24.60M
64.98%-17.62M
-10.59%-55.72M
48.18%-26.53M
16.70%-34.09M
-57.12%-50.32M
-175.06%-50.39M
-240.29%-51.19M
---40.93M
---32.02M
---18.32M
---15.04M
Net income attributable to controlling interests
-96.99%-42.41M
-48.26%-27.85M
-28.24%-32.73M
-28.45%-26.88M
10.52%-21.53M
-139.35%-18.79M
78.20%-25.52M
14.92%-20.93M
-36.54%-24.06M
185.68%47.74M
-341.39%-117.09M
27.85%-24.60M
64.98%-17.62M
-10.59%-55.72M
48.18%-26.53M
16.70%-34.09M
-57.12%-50.32M
-175.06%-50.39M
-240.29%-51.19M
---40.93M
---32.02M
---18.32M
---15.04M
Net income attributable to common shareholders
-96.99%-42.41M
-48.26%-27.85M
-28.24%-32.73M
-28.45%-26.88M
10.52%-21.53M
-139.35%-18.79M
78.20%-25.52M
14.92%-20.93M
-36.54%-24.06M
185.68%47.74M
-341.39%-117.09M
27.85%-24.60M
64.98%-17.62M
-10.59%-55.72M
48.18%-26.53M
16.70%-34.09M
-57.12%-50.32M
-175.06%-50.39M
-240.29%-51.19M
---40.93M
---32.02M
---18.32M
---15.04M
Basic earnings per share
-44.70%-0.12
-11.36%-0.08
2.78%-0.09
-0.36%-0.09
23.17%-0.08
-130.87%-0.07
89.77%-0.10
76.52%-0.09
62.65%-0.10
123.00%0.23
-43.75%-0.93
54.92%-0.38
78.87%-0.28
25.42%-0.99
51.89%-0.65
22.22%-0.85
-52.26%-1.32
-149.12%-1.32
-209.11%-1.35
---1.09
---0.87
---0.53
---0.44
Diluted earnings per share
-44.70%-0.12
-11.36%-0.08
2.78%-0.09
-0.36%-0.09
23.17%-0.08
-130.87%-0.07
89.77%-0.10
76.52%-0.09
62.65%-0.10
123.00%0.23
-43.75%-0.93
54.92%-0.38
78.87%-0.28
25.42%-0.99
51.89%-0.65
22.22%-0.85
-52.26%-1.32
-149.12%-1.32
-209.11%-1.35
---1.09
---0.87
---0.53
---0.44
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Taysha Gene Therapies Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing TSHA stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Taysha Gene Therapies Inc's revenue at year end?

Taysha Gene Therapies Inc reported 9.77M in revenue for fiscal year 2025, up from 8.33M in the previous year.

What was Taysha Gene Therapies Inc's net income for the year?

Taysha Gene Therapies Inc posted -109.00M in net income for fiscal year 2025.

How much net income did Taysha Gene Therapies Inc post in the last quarter?

Taysha Gene Therapies Inc reported -42.41M in net income for the latest quarter。

What was Taysha Gene Therapies Inc's annual operating profit?

Taysha Gene Therapies Inc's operating income was -110.50M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.